PCDHGB6 and non-small cell lung carcinoma: Sandoval et al. discovered a methylation signature based on 10 sites (HOXA9, C1orf114, TRH, HIST1H4F, SP9, PCDHGB6, OTX2, NPBWR1, TRIM58, and ALX1) that effectively distinguished stage I NSCLC patients with high recurrence risk and low risk 57.Conventionally, molecular or epigenetic biomarkers are often identified by comparing the genomic or epigenomic landscapes of two groups with diverse outcomes.